Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phibro Animal Health

West Pharmaceutical Services

Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.

Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD

Cerner

Allscripts Healthcare Solutions

NextGen Healthcare Inc

Here we look at three stocks, MDRX, CERN and RMD, that investors can keep a watch on the back of their robust digital health prospects.

Digital Health Momentum is Here to Stay: 3 MedTech Stocks in Focus

Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.

ResMed (RMD) Hits a New 52-Week High: What's Driving It?

A competitor's misfortune could be a big opportunity for the medical device giant.

Why ResMed Stock Exploded Higher This Week

RMD stock is also up 179% from the levels of around $85 seen toward the end of 2017. The rise over the last three years or so is justified given the company's robust fundamentals.

Despite Philips Recall ResMed Stock Appears Fully Priced

Although ResMed Inc's (NYSE:RMD) long-term outlook is positive, the market seems to have over-reacted to rival Koninklijke Philips NV's (NYSE:PHG) recall notification of certain sleep and respiratory care devices for the U.S., according to BofA Securities. The ResMed Analyst: Lyanne Harrison downgraded the rating for ResMed from Neutral to Underperform, while raising the price target from $216 to $221.

5 Reasons Why ResMed Gets Downgrade From BofA Securities

Royal Philips

The full U.S. launch of ResMed (RMD) AirSense 11 is expected any time in 2021, which might receive bigger market acceptance capitalizing on its current peer position.

ResMed (RMD) Rallies as Philips Falters on Mass Product Recall

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ResMed (RMD) Moves 6% Higher: Will This Strength Last?

Lordstown Motors

Checkpoint Therapeutics

Helix Energy Solutions Group

Home Point Capital

Morgan Stanley

Omnicell

Renewable Energy Group

Weatherford International PLC

With the trading day about halfway over, the markets were trading sideways yet again, and it seems like the major averages may be stuck on this plateau.

Lordstown, Morgan Stanley, ResMed and More Wednesday Afternoon Analyst Calls

Trade Desk

Gambling can be fun, but growing sales and profits are what matter for long-term gains.

2 Stocks That Are Much More Likely Than AMC to Make You Rich

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at approximately 1:20 p.m. (Eastern Daylight Time) via video webcast.

ResMed Announces Participation in the Goldman Sachs 42nd Annual Global Healthcare Conference

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021, beginning at approximately 1:20 p.m. (Central Daylight Time) via video webcast.

ResMed Announces Participation in the William Blair 41st Annual Growth Stock Conference

Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.

ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss

ResMed Inc. (RMD) CEO Mick Farrell on Q3 2021 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 6.56% and -2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q3 Earnings Top Estimates

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Wednesday, May 5, 2021, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast.

ResMed Announces Participation in the 23rd Annual Macquarie Australia Conference

Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.

ResMed (RMD) to Report Q3 Earnings: What's in the Offing?

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ResMed (RMD) Q3 Earnings Expected to Decline

Align Technology

Vertex Pharmaceuticals

Well-known guidance from Warren Buffett can help us identify opportunities in an expensive market.

3 Top Value Stocks in Healthcare to Buy Right Now

Inspire Medical Systems Inc

Vivos Therapeutics

Three stocks to have on your radar in the healthcare space.

Investing in Sleep Apnea Companies

Nyxoah Reports Full Year 2020 Results

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021

The stock of ResMed (NYSE:RMD, 30-year Financials) appears to be modestly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded.

ResMed Stock Appears To Be Modestly Overvalued

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer and Brett Sandercock, chief financial officer, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on Tuesday, March 23, 2021, beginning at approximately 4:15 p.m. (Eastern Daylight Time) via video webcast. More information about this event, including access to the live webcast, may be accessed by visiting

ResMed Announces Participation in KeyBanc's Capital Markets' Life Sciences & MedTech Investor Forum

SAN DIEGO--(BUSINESS WIRE)---- $RMD #sleep--ResMed's 2021 U.S. Consumer Sleep Survey reveals how many Americans have symptoms of a common sleep disorder, but aren't concerned about them.

News for ResMed Stock (RMD)